Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TFFP |
---|---|---|
09:32 ET | 4501 | 0.9189 |
09:44 ET | 6000 | 0.911 |
09:53 ET | 600 | 0.9299 |
09:55 ET | 3757 | 0.92 |
10:04 ET | 105 | 0.9599 |
10:24 ET | 740 | 0.92 |
10:26 ET | 100 | 0.9596 |
10:33 ET | 100 | 0.94 |
10:47 ET | 100 | 0.95 |
10:51 ET | 865 | 0.94 |
10:58 ET | 600 | 0.95 |
11:05 ET | 550 | 0.95 |
11:41 ET | 1300 | 0.94 |
11:43 ET | 1000 | 0.940101 |
11:48 ET | 1000 | 0.942451 |
11:50 ET | 4555 | 0.94 |
11:52 ET | 4362 | 0.9226 |
11:57 ET | 3703 | 0.92 |
12:08 ET | 1900 | 0.92 |
12:24 ET | 780 | 0.96 |
12:26 ET | 3000 | 0.9475 |
12:32 ET | 2000 | 0.9354 |
12:35 ET | 1730 | 0.9477 |
12:46 ET | 2900 | 0.93 |
12:57 ET | 404 | 0.9312 |
01:08 ET | 400 | 0.9598 |
01:31 ET | 200 | 0.9563 |
01:49 ET | 100 | 0.956 |
01:51 ET | 130 | 0.956 |
02:00 ET | 5580 | 0.93 |
02:02 ET | 200 | 0.9573 |
02:14 ET | 500 | 0.95 |
02:21 ET | 200 | 0.93 |
02:23 ET | 127 | 0.96 |
02:27 ET | 1100 | 0.93 |
03:15 ET | 1114 | 0.93 |
03:17 ET | 100 | 0.935 |
03:19 ET | 100 | 0.945 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TFF Pharmaceuticals Inc | 34.2M | -0.7x | --- |
Protara Therapeutics Inc | 34.9M | -0.9x | --- |
Immix Biopharma Inc | 33.4M | -0.7x | --- |
Satsuma Pharmaceuticals Inc | 32.5M | -0.5x | --- |
Better Therapeutics Inc | 32.2M | -0.5x | --- |
ARCA Biopharma Inc | 32.0M | -2.2x | --- |
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF), technology platform. TFF platform is designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. TFF Pharmaceuticals has two lead drug candidates: Inhaled Voriconazole Powder (TFF Vori) and Inhaled Tacrolimus Powder (TFF Tac-Lac). The Company is engaged in the joint development of an inhaled SARS-CoV2 Monoclonal Antibody in collaboration with Augmenta BioWorks and a dry powder formulation of niclosamide in collaboration agreement. It is also actively engaged in the analysis and testing of dry powder formulations of several drugs and vaccines through topical, ocular and nasal applications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.2M |
---|---|
Revenue (TTM) | $195.0K |
Shares Outstanding | 36.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.36 |
Book Value | $1.53 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 175.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -17,735.84% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.